EN DE
Watch Navamedic ASA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Navamedic ASA (NAVA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Navamedic ASA stock NOK 4.90, price NOK 10.25, that is 52.2% below the price, quality 25 out of 100. Rating: strongly overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare NO · ISIN NO0010205966

NA Navamedic ASA logo Thin data Nov 6, 2026

Navamedic ASA

NAVA · OL
Very expensive, weak quality

Our calculation puts a fair price 52% below what the stock costs today.

Low debt
Generates free cash flow
Mixed Growth (revenue 5y +21.9 %/yr in NOK)
Revenue last quarter 13% below a year ago.
Fair value kr 4.90 · Strongly overvalued
Quality 25/100
Loss-making · -4.5% net margin (TTM)
Trails peers (1/12)
Narrow moat 15/100 · thin data
Thin data
⚠ Dilution
Watch Navamedic ASA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 42.60 kr 10.25 Fair Value kr 4.90 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range kr 10.25 – kr 42.60 · fair‑value band kr 2.33 – kr 7.48 · the kr 10.25 price screens above the kr 4.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.

Follow Navamedic in your weekly email

Every Wednesday you see whether Navamedic is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally.

Show moreShow less

Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics.

The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases, fat metabolism, renal, nutritional support, and ketogenic diet.

In addition, it provides consumer health products consisting of non-prescription drugs and health care products for erectile dysfunction, pain, gastro-related problems, and others primarily through pharmacies and drugstores; prescription medicines covering obesity, Parkinson's disease, urology, and cardiology; and antibiotics.

It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.

Stock analysis

Navamedic ASA (NAVA) currently trades at kr 10.25, while our model-based Fair Value estimate is kr 4.90, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of kr 26.24 per share, and 9 of the 13 models we run sit above the kr 10.25 price.

Bear case: the Earnings-Based group reads lowest at kr 2.78, and 4 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: kr 2.33 (bear) to kr 7.48 (bull), the price of kr 10.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Navamedic ASA reported revenue of 565M NOK in FY2025 versus 278M NOK in FY2021, a compound +19.4%/yr. Reported net income was −23.5M NOK in FY2025.

Key figures

Market cap 246M NOK (≈ $26.0M) Micro · P/S ratio 0.46 · EPS (TTM) kr −1.08 · Net margin −4.5% · Return on equity −10.0% · Return on assets (EBIT) 5.3% (5-year average) · Operating margin −0.2% · Revenue (TTM) 556M NOK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at −52%, NAVA screens richer than that median.

Fair Value models

Bear kr 2.33 Fair Value kr 4.90 Bull kr 7.48
Price kr 10.25 · Downside -52.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF kr 17.71 kr 38.92 kr 85.46 74
Growth DCF kr 17.33 kr 37.58 kr 77.14 73
5Y EBITDA Exit kr 16.68 kr 34.93 kr 58.74 72
All 13 models by family
DCF Models
FCF DCF kr 17.71 kr 38.92 kr 85.46 74
Owner Earnings kr 4.15 kr 12.55 kr 29.29 68
5Y Revenue Exit kr 7.04 kr 13.98 kr 23.27 70
5Y EBITDA Exit kr 16.68 kr 34.93 kr 58.74 72
10Y Revenue Exit kr 9.92 kr 18.07 kr 30.59 64
10Y EBITDA Exit kr 16.91 kr 34.41 kr 62.90 65
Earnings-Based
EPV kr 1.77 kr 2.78 kr 3.69 72
Multiples
EV/EBIT kr 2.74 kr 5.77 kr 8.80 62
EV/EBITDA kr 14.87 kr 21.94 kr 29.01 66
EV/Revenue kr 0.1400 kr 2.92 kr 5.70 46
Growth DCF
Growth DCF kr 17.33 kr 37.58 kr 77.14 73
Rev-Margin DCF kr 7.04 kr 13.93 kr 23.35 70
Economic Profit
ROIC Compounder kr 1.77 kr 2.78 kr 3.69 71

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 23
Are margins and returns getting better?
Cashflow 50
Do the profits arrive as real cash?
Financial strength 37
Debt, balance sheet and risk of trouble
Investment 39
Does it invest with discipline instead of growing at any price?
Low Volatility 71
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 54/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.9%
Start year 2020 (pandemic). Over 10 years: +8.6% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2.3% (2020) → 3.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (Norway: IMF forecast 2.4% a year to 2030, 3.3% from 2016 to 2025) that is about −0.4% a year for the price and +0.4% for the forecasts.
Forecast 2026 (sales)+3.0%
Forecast 2027 (sales)+3.0%
Projected 2028 (sales)+2.8%
Projected 2029 (sales)+2.7%
Projected 2030 (sales)+2.6%

NAVA screens overvalued: fair value 52% below the price. Compare with McKesson Corporation →

Compare Navamedic ASA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks

Beats the industry median on 1/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −52.2% · Bottom 25%
Profitability
Return on assets −3.2% · Bottom 25%
Net margin (12 months) −4.5% · Bottom 25%
Operating margin (12 months) −0.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −13.2% · Bottom 25%
Balance sheet
Debt / equity 0.49× · Highest 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B 0.74× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.44× · Pricier than median
Price / free cash flow (fiscal year) 10.6× · Cheaper than median
EV/EBITDA 7.8× · Pricier than median
PEG 1.38× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 38
FUTURE (revenue growth)0 · sector 24
PAST (return on equity)0 · sector 28
HEALTH (low debt)75 · sector 97
DIVIDEND (yield)0 · sector 54

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$17.16 HK$51.48 +200% vs NAVA
Jointown Pharmaceutical Group 600998 ¥5.24 ¥11.56 +121% vs NAVA
Shanghai Pharmaceuticals Holding 601607 ¥16.76 ¥35.78 +113% vs NAVA
China National Medicines Corporation 600511 ¥29.29 ¥58.47 +100% vs NAVA
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥20.09 ¥26.64 +33% vs NAVA
Cencora, Inc COR $333.56 $341.58 +2% vs NAVA
Henry Schein, Inc HSIC $86.05 $78.69 −9% vs NAVA
McKesson Corporation MCK $1,061 $822.74 −22% vs NAVA
Galenica AG GALE CHF 89.45 CHF 61.79 −31% vs NAVA
Cardinal Health, Inc CAH $271.72 $163.14 −40% vs NAVA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Navamedic ASA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Navamedic ASA Fair Value". https://www.fairvalue-calculator.com/stock/NAVA.OL

Frequently asked questions

Is Navamedic ASA (NAVA) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of kr 4.90 versus a price of kr 10.25, about 52% lower (overvalued).
What is the fair value of NAVA?
Our model-based fair value for Navamedic ASA is kr 4.90 (as of Nov 6, 2026), built from audited fundamentals. The current price: kr 10.25.
What is the quality score of NAVA?
Navamedic ASA has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Navamedic ASA (NAVA)?
Our model-based price target is the fair value of kr 4.90 (as of Nov 6, 2026) from 13 valuation models. Cautious scenario kr 2.33, optimistic scenario kr 7.48. It is a calculation from audited fundamentals, not an analyst target.
What is the Navamedic ASA stock forecast for 2026?
Our models put fair value at kr 4.90, about 52% lower versus a price of kr 10.25 (overvalued). Cautious scenario kr 2.33, optimistic scenario kr 7.48. The calculation is refreshed regularly with new filings.
What is the revenue of Navamedic ASA (NAVA)?
Navamedic ASA reported trailing-twelve-month revenue of about 556M NOK (latest available figure, as of Nov 6, 2026).
What growth is priced into Navamedic ASA (NAVA)?
For today's price to be fair in a discounted-cash-flow model, Navamedic ASA would have to grow free cash flow by +2.0 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.9 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of NAVA use?
Our models discount Navamedic ASA at 8.3 %: a base by market capitalisation (nano), damped by beta 0.25, country premium for Norway. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Navamedic ASA that is +2.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has Navamedic ASA (NAVA) delivered so far?
Over the past 5 years revenue at Navamedic ASA grew +21.9 % a year. The price currently implies free-cash-flow growth of +2.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Navamedic ASA (NAVA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Navamedic ASA (+2.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Navamedic ASA (NAVA)?
The free-cash-flow yield on the price is 9.44 %: that much free cash flow Navamedic ASA produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Navamedic ASA (NAVA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Navamedic ASA it is kr 4.90 per share (as of Nov 6, 2026), against a price of kr 10.25. It is the blended result of 13 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit).
Is Navamedic ASA stock overvalued or undervalued in 2026?
As of Nov 6, 2026, NAVA trades above its calculated fair value: price kr 10.25, fair value kr 4.90, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NAVA?
No. The price is what the market pays today (kr 10.25); the fair value is what the company's own numbers justify (kr 4.90). For Navamedic ASA the two are kr 5.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Navamedic ASA worth?
The market values Navamedic ASA at about 246M NOK (market capitalisation, as of Nov 6, 2026). Per share that is kr 10.25; our models calculate a fair value of kr 4.90 per share.
What do the bullish and bearish scenarios say about NAVA?
Our models span a range for Navamedic ASA: cautious scenario kr 2.33, base kr 4.90, optimistic kr 7.48 per share (as of Nov 6, 2026, price kr 10.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of NAVA?
The PEG ratio of Navamedic ASA is 1.38 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Navamedic ASA (NAVA)?
Balance-sheet figures for Navamedic ASA (as of Nov 6, 2026): return on equity −10.0%, debt of 0.49 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is NAVA from its 52-week high?
Navamedic ASA trades at kr 10.25, about 61% below its 52-week high of kr 26.00 and at the low of kr 10.25 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 4.90 is for.
Which stocks are comparable to Navamedic ASA?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Navamedic ASA stock attractive at the current price?
The data as of Nov 6, 2026: price kr 10.25, calculated fair value kr 4.90 (−52%), Quality Score 25/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NAVA calculated?
We run Navamedic ASA through 13 models from 5 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of kr 4.90 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Navamedic ASA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Navamedic ASA (NAVA)?
The closing price on Nov 6, 2026 was kr 10.25. Our model-based fair value is kr 4.90, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Navamedic ASA right now?
The price sits above even our optimistic bull case (kr 7.48). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (kr 2.33 to kr 7.48). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Navamedic ASA

How large is the market capitalisation of Navamedic ASA (NAVA)?
The market capitalisation of Navamedic ASA is 246M NOK (≈ $26.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Navamedic ASA (NAVA)?
The price-to-sales ratio of Navamedic ASA is 0.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Navamedic ASA (NAVA)?
Earnings per share at Navamedic ASA are kr −1.08. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Navamedic ASA (NAVA)?
The net margin of Navamedic ASA is −4.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Navamedic ASA (NAVA)?
The return on equity (ROE) of Navamedic ASA is −10.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Navamedic ASA (NAVA)?
On an EBIT basis the return on assets of Navamedic ASA is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Navamedic ASA (NAVA)?
The operating margin of Navamedic ASA is −0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Navamedic ASA (NAVA)?
Revenue at Navamedic ASA is growing −13.2% versus a year earlier (3y avg +13.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Navamedic ASA (NAVA)?
Earnings per share at Navamedic ASA are growing +533% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Navamedic ASA (NAVA) carry?
The net debt of Navamedic ASA is 152M NOK (fiscal year 2025, ≈ 6.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Navamedic ASA in the live analysis

One click puts Navamedic ASA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.